About Scholar Rock Holding Corporation
https://scholarrock.comScholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
CEO
David L. Hallal
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 3 of 136
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Truist Securities
Buy
HC Wainwright & Co.
Buy
BMO Capital
Outperform
Barclays
Overweight
JP Morgan
Overweight
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FMR LLC
Shares:14.01M
Value:$638.67M
SIREN, L.L.C.
Shares:9.25M
Value:$421.62M
PRICE T ROWE ASSOCIATES INC /MD/
Shares:6.88M
Value:$313.73M
Summary
Showing Top 3 of 262
About Scholar Rock Holding Corporation
https://scholarrock.comScholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $103.13M ▼ | $-102.22M ▲ | 0% | $-0.9 ▲ | $-100.46M ▲ |
| Q2-2025 | $0 | $111.69M ▲ | $-110.03M ▼ | 0% | $-0.98 ▼ | $-108.41M ▼ |
| Q1-2025 | $0 | $76.7M ▲ | $-74.72M ▼ | 0% | $-0.67 | $-76.7M ▼ |
| Q4-2024 | $0 | $68.96M ▲ | $-66.45M ▼ | 0% | $-0.67 ▼ | $-66.06M ▼ |
| Q3-2024 | $0 | $64.33M | $-64.48M | 0% | $-0.66 | $-64.33M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $369.63M ▲ | $411.72M ▲ | $166.72M ▲ | $245M ▲ |
| Q2-2025 | $295.01M ▼ | $340.05M ▼ | $106.75M ▲ | $233.29M ▼ |
| Q1-2025 | $364.38M ▼ | $407.55M ▼ | $95.22M ▼ | $312.33M ▼ |
| Q4-2024 | $437.28M ▲ | $474.92M ▲ | $106.29M ▲ | $368.63M ▲ |
| Q3-2024 | $139.06M | $179.13M | $99.94M | $79.2M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-102.22M ▲ | $-68.92M ▲ | $59.7M ▼ | $144.47M ▲ | $135.25M ▲ | $-69.01M ▲ |
| Q2-2025 | $-110.03M ▼ | $-76.94M ▲ | $85.47M ▲ | $6.47M ▲ | $15M ▲ | $-77.16M ▲ |
| Q1-2025 | $-74.72M ▼ | $-78.67M ▼ | $34.55M ▲ | $4.17M ▼ | $-39.95M ▼ | $-78.95M ▼ |
| Q4-2024 | $-66.45M ▼ | $-49.51M ▲ | $-195.37M ▼ | $346.37M ▲ | $101.49M ▲ | $-49.53M ▲ |
| Q3-2024 | $-64.48M | $-52.45M | $35.31M | $166K | $-16.98M | $-52.49M |
CEO
David L. Hallal
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 3 of 136
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Truist Securities
Buy
HC Wainwright & Co.
Buy
BMO Capital
Outperform
Barclays
Overweight
JP Morgan
Overweight
Piper Sandler
Overweight
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
FMR LLC
Shares:14.01M
Value:$638.67M
SIREN, L.L.C.
Shares:9.25M
Value:$421.62M
PRICE T ROWE ASSOCIATES INC /MD/
Shares:6.88M
Value:$313.73M
Summary
Showing Top 3 of 262